Neuroprotective agents in schizophrenia and affective disorders

Expert Opinion on Pharmacotherapy
Michael KrebsMartin Schaefer

Abstract

With the exception of dementia, the use of neuroprotective agents in psychiatric disorders is not yet well established. However, recent data from brain imaging studies and clinical trials support the view that neurodegenerative mechanisms may play a role in the pathophysiology of schizophrenia and affective disorders. Further evidence for the use of neuroprotective agents can be drawn from the findings that second-generation antipsychotics, mood stabilizers and antidepressants have been shown to have neuroprotective effects in vitro and in vivo. Neuroprotective agents as add-on therapies (e.g., modafinil, erythropoietin, glycine, D-serine, memantine and celecoxib) are currently being evaluated in schizophrenia and related disorders. This paper reviews the current options for neuroprotective treatment approaches focusing on schizophrenia and affective disorders.

References

Mar 1, 1994·Neurobiology of Aging·D D Schoepp, A I Sacaan
Apr 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·E AllevaL Aloe
Jun 5, 1998·Biological Psychiatry·K L DavisP Powchik
Jul 11, 1998·Journal of Neural Transmission·R R DawirsG Teuchert-Noodt
Jan 19, 1999·Archives of General Psychiatry·U Heresco-LevyM Lichtenstein
Aug 11, 1999·Trends in Neurosciences·U DirnaglM A Moskowitz
Oct 26, 1999·Archives of General Psychiatry·S M DursunH Milliken
Sep 15, 2000·Journal of Neurochemistry·G ChenH K Manji
Feb 24, 2001·Journal of Neural Transmission·R GaliliD Offen
Oct 11, 2001·Journal of Clinical Psychopharmacology·D C GoffG Lynch
Nov 8, 2001·European Archives of Psychiatry and Clinical Neuroscience·H Ehrenreich, A L Sirén
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Guochuan Tsai, Joseph T Coyle
Mar 1, 2002·The American Journal of Psychiatry·Uriel Heresco-LevyDaniel C Javitt
Mar 5, 2002·Nature·Henriette van PraagFred H Gage
Jun 4, 2002·The American Journal of Psychiatry·Norbert MüllerMarkus J Schwarz
Jun 20, 2002·Bipolar Disorders·Xiaohua LiRichard S Jope
Jul 2, 2002·The American Journal of Psychiatry·Trina B Allen, Joseph P McEvoy
Jul 12, 2002·Journal of Neuroscience Research·Ou BaiXin-Min Li
Jul 12, 2002·Journal of Neuroscience Research·Chandramohan G WakadeFung-Chow Chiu
Jul 30, 2002·Progress in Brain Research·Brian S Meldrum
Aug 16, 2002·Bipolar Disorders·Carrol D'Sa, Ronald S Duman
Nov 7, 2002·Archives of General Psychiatry·Wiepke CahnRené S Kahn
Jan 28, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·L Hosák, J Libiger

❮ Previous
Next ❯

Citations

Oct 6, 2007·Molecular Neurobiology·Gerhard Rammes, Rainer Rupprecht
Jan 17, 2013·Antioxidants & Redox Signaling·Marilena ColaiannaLuigia Trabace
Dec 18, 2010·Neuromolecular Medicine·Joanna K SoczynskaRoger S McIntyre
Oct 24, 2013·Expert Opinion on Drug Discovery·Marco A GradosDiandra Fortune
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Roger S McIntyreSidney H Kennedy
May 5, 2007·European Journal of Pharmacology·Marsha M DopheideDennis K Miller
Mar 11, 2010·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Christoph U CorrellBarbara A Cornblatt
Oct 18, 2014·Journal of Clinical Neurology·Hyun Young KimSeung Hyun Kim
May 8, 2014·The Australian and New Zealand Journal of Psychiatry·Justin DavisMichael Berk
Sep 1, 2009·Irish Journal of Psychological Medicine·Caragh Behan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2022 Meta ULC. All rights reserved